Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. I − Optimization of separation conditions

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1032, Issue , 2016, Pages 103-111

  Sarrut, Morgan ^a   Corgier, Amélie ^a   Fekete, Szabolcs ^b   Guillarme, Davy ^b   Lascoux, David ^d   Janin Bussat, Marie Claire ^c   Beck, Alain ^c   Heinisch, Sabine ^a  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c Centre d'Immunologie Pierre Fabre   (France)

^d Waters SAS   (France)

Author keywords

ADC; Adcetris ; Antibody drug conjugate; Brentuximab vedotin; HICxRPLC QTOF MS; On line comprehensive 2D LC

Indexed keywords

ANTIBODIES; HYBRID INTEGRATED CIRCUITS; HYDROPHOBIC CHROMATOGRAPHY; HYDROPHOBICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRECIPITATION (CHEMICAL); QUALITY CONTROL; SPECTROMETRY;

ANTIBODY-DRUG CONJUGATES; BRENTUXIMAB VEDOTIN; HICXRPLC-QTOF-MS; HIGH RESOLUTION MASS SPECTROMETRY; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; ON-LINE COMPREHENSIVE 2D-LC; REVERSED PHASE LIQUID-CHROMATOGRAPHY; STRUCTURAL CHARACTERIZATION;

CHROMATOGRAPHY;

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; BRENTUXIMAB VEDOTIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; MASS SPECTROMETRY; MEASUREMENT PRECISION; ON LINE COMPREHENSIVE TWO DIMENSIONAL LIQUID CHROMATOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; CHEMICAL PHENOMENA; CHEMISTRY; DEVICES; EQUIPMENT DESIGN; ISOLATION AND PURIFICATION; PROCEDURES;

CHROMATOGRAPHY, REVERSE-PHASE; EQUIPMENT DESIGN; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMMUNOCONJUGATES; MASS SPECTROMETRY;

EID: 84991701988     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2016.06.048     Document Type: Article

References (27)

1. [1] Beck, A., Wurch, T., Bailly, C., Corvaia, N., Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10 (2010), 345–352, 10.1038/nri2747.
2. [2] Le, L.N., Moore, J.M.R., Ouyang, J., Chen, X., Nguyen, M.D.H., Galush, W.J., Profiling antibody drug conjugate positional isomers: a system-of-equations approach. Anal. Chem. 84 (2012), 7479–7486, 10.1021/ac301568f.
3. [3] Senter, P.D., Sievers, E.L., The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 30 (2012), 631–637, 10.1038/nbt.2289.
4. [4] Teicher, B.A., Chari, R.V.J., Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 17 (2011), 6389–6397, 10.1158/1078-0432.CCR-11-1417.
5. [5] Wiggins, B., Liu-Shin, L., Yamaguchi, H., Ratnaswamy, G., Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody–drug conjugates. J. Pharm. Sci. 104 (2015), 1362–1372, 10.1002/jps.24338.
6. [6] Haverick, M., Mengisen, S., Shameem, M., Ambrogelly, A., Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications. mAbs 6 (2014), 852–858, 10.4161/mabs.28693.
7. [7] Ouyang, J., Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-Performance liquid chromatography. Ducry, L., (eds.) Antib.-Drug Conjug., 2013, Humana Press, Totowa, NJ, 275–283 http://link.springer.com/10.1007/978-1-62703-541-5_17 (accessed 10.30.15.).
8. [8] Valliere-Douglass, J.F., Hengel, S.M., Pan, L.Y., Approaches to interchain cysteine-linked ADC characterization by mass spectrometry. Mol. Pharm. 12 (2015), 1774–1783, 10.1021/mp500614p.
9. [9] Pan, L.Y., Salas-Solano, O., Valliere-Douglass, J.F., Conformation and dynamics of interchain cysteine-linked antibody-drug conjugates as revealed by hydrogen/deuterium exchange mass spectrometry. Anal. Chem. 86 (2014), 2657–2664, 10.1021/ac404003q.
10. [10] Beck, A., Wagner-Rousset, E., Ayoub, D., Van Dorsselaer, A., Sanglier-Cianférani, S., Characterization of therapeutic antibodies and related products. Anal. Chem. 85 (2013), 715–736, 10.1021/ac3032355.
11. [11] Wakankar, A., Chen, Y., Gokarn, Y., Jacobson, F.S., Analytical methods for physicochemical characterization of antibody drug conjugates. mAbs 3 (2011), 161–172, 10.4161/mabs.3.2.14960.
12. [12] Beck, A., Cianferani, S., Harnessing the benefits of mass spectrometry for in-depth antibody drug conjugates analytical characterization, LC-GC. Eur. Adv. Biopharm. Anal. 2 (2015), 24–30.
13. [13] Beck, A., Terral, G., Debaene, F., Wagner-Rousset, J., Janin-Bussat, O., Dorsselaer, A.V., Cianférani, S., Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. Expert Rev. Proteomics, 2015, 10.1586/14789450.2016.1132167 (Epub ahead of print).
14. [14] Birdsall, R.E., McCarthy, S.M., Janin-Bussat, M.C., Perez, M., Haeuw, J.-F., Chen, W., Beck, A., A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection. mAbs 8 (2016), 306–317, 10.1080/19420862.2015.1116659.
15. [15] K. Sandra, G. Vanhoenacker, I. Vandenheede, M. Steenbeke, M. Joseph, P. Sandra, Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine, J. Chromatogr. B (n.d.). 10.1016/j.jchromb.2016.04.040.
16. [16] Debaene, F., Bœuf, A., Wagner-Rousset, E., Colas, O., Ayoub, D., Corvaïa, N., Van Dorsselaer, A., Beck, A., Cianférani, S., Innovative native MS methodologies for antibody drug conjugate characterization: high resolution native MS and IM-MS for average DAR and DAR distribution assessment. Anal. Chem. 86 (2014), 10674–10683, 10.1021/ac502593n.
17. [17] Janin-Bussat, M.-C., Dillenbourg, M., Corvaia, N., Beck, A., Klinguer-Hamour, C., Characterization of antibody drug conjugate positional isomers at cysteine residues by peptide mapping LC–MS analysis. J. Chromatogr. B 981–982 (2015), 9–13, 10.1016/j.jchromb.2014.12.017.
18. [18] Birdsall, R.E., Shion, H., Kotch, F.W., Xu, A., Porter, T.J., Chen, W., A rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography. mAbs 7 (2015), 1036–1044, 10.1080/19420862.2015.1083665.
19. [19] Sarrut, M., D'Attoma, A., Heinisch, S., Optimization of conditions in on-line comprehensive two-dimensional reversed phase liquid chromatography. Experimental comparison with one-dimensional reversed phase liquid chromatography for the separation of peptides. J. Chromatogr. A 1421 (2015), 48–59, 10.1016/j.chroma.2015.08.052.
20. [20] Fausnaugh, J.L., Kennedy, L.A., Regnier, F.E., Comparison of hydrophobic-interaction and reversed-phase chromatography of proteins. J. Chromatogr. 317 (1984), 141–155, 10.1016/S0021-9673(01)91654-1.
21. [21] Cusumano, A., Guillarme, D., Beck, A., Fekete, S., Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydotphobic interaction chromatography, Part 2: Optimization of the phase sytem. J. Pharm. Biomed. Anal., 2016 (submitted for publication).
22. ® derivatives: effects of neutral salts on the adsorption of proteins. J. Chromatogr. 131 (1977), 99–108, 10.1016/S0021-9673(00)80924-3.
23. [23] Snyder, L.R., Dolan, J.W., Gant, J.R., Gradient elution in high-performance liquid chromatography: i. Theoretical basis for reversed-phase systems. J. Chromatogr. A 165 (1979), 3–30, 10.1016/S0021-9673(00)85726-X.
24. [24] Sarrut, M., Crétier, G., Heinisch, S., Theoretical and practical interest in UHPLC technology for 2D-LC. TrAC Trends Anal. Chem. 63 (2014), 104–112, 10.1016/j.trac.2014.08.005.
25. [25] Bobály, B., Beck, A., Fekete, J., Guillarme, D., Fekete, S., Systematic evaluation of mobile phase additives for the LC–MS characterization of therapeutic proteins. Talanta 136 (2015), 60–67, 10.1016/j.talanta.2014.12.006.
26. [26] Hamblett, K.J., Senter, P.D., Chace, D.F., Sun, M.M.C., Lenox, J., Cerveny, C.G., Kissler, K.M., Bernhardt, S.X., Kopcha, A.K., Zabinski, R.F., Meyer, D.L., Francisco, J.A., Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10 (2004), 7063–7070, 10.1158/1078-0432.CCR-04-0789.
27. [27] Sievers, E.L., Senter, P.D., Antibody-Drug conjugates in cancer therapy. Annu. Rev. Med. 64 (2013), 15–29, 10.1146/annurev-med-050311-201823.